Related Experiment Video

Updated: Nov 22, 2025

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.4K

Diagnosis and management of giant cell arteritis: Major review

Sumu Simon1, Jem Ninan2, Pravin Hissaria3

  • 1Department of Ophthalmology and South Australian Institute of Ophthalmology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.

Clinical & Experimental Ophthalmology
|January 11, 2021
PubMed

Insights

Giant cell arteritis is a serious condition requiring prompt diagnosis to prevent vision loss and stroke. While tests aid diagnosis, clinical skills are crucial, and new biologic treatments may improve outcomes.

Area of Science:

  • Vascular Medicine
  • Rheumatology
  • Ophthalmology

Background:

  • Giant cell arteritis (GCA) presents a significant medical emergency due to the risk of irreversible blindness and cerebrovascular accidents.
  • Early diagnosis is critical to prevent severe complications.

Purpose of the Study:

  • To highlight the diagnostic challenges and current treatment paradigms for Giant Cell Arteritis.
  • To discuss the potential of future therapeutic strategies.

Main Methods:

  • Review of clinical presentation, diagnostic tools, and treatment protocols for GCA.
  • Emphasis on the integration of clinical acumen with diagnostic modalities.
  • Exploration of emerging biologic therapies.

Main Results:

  • Diagnostic aids include inflammatory markers, temporal artery biopsy, and imaging, but clinical judgment remains paramount.
  • Glucocorticoids are the standard treatment, despite significant rates of relapse and adverse effects.
  • Biologic agents show promise for future GCA management.

Conclusions:

  • Timely diagnosis of Giant Cell Arteritis relies on a combination of clinical skills and diagnostic tests.
  • Current treatments have limitations, necessitating the exploration of novel therapeutic approaches.
  • Targeted biologic therapies represent a potential advancement in managing GCA.

Keywords:
clinical featuresgiant cell arteritismodern imaging modalitiessteroid sparing agentssteroids

More Related Videos

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

573
Microsurgical Creation of Giant Bifurcation Aneurysms in Rabbits for the Evaluation of Endovascular Devices07:21

Microsurgical Creation of Giant Bifurcation Aneurysms in Rabbits for the Evaluation of Endovascular Devices

Published on: September 8, 2023

901

Related Concept Videos

Aneurysm III: Interprofessional Care01:26

Aneurysm III: Interprofessional Care

Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
110
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
175
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
131
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
126
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
150
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
72